Rimantadine機轉

�ܬy�P�s��Xofluza����
?Xofluza�u�n�f�A�@���A48�p�ɤ����Īv���y�P��
�y�P(Influenza )�O�@�ث�ʯf�r�ʩI�l�D�e�f�A�D�n�P�f�쬰�y�P�f�rA���PB���A�o�@�f�{��1��2�P�A�D�n�g�ѭ��z�α�IJ�f�H�����c���ӷP�V�A�i�o�ͦb�Ҧ��~�ּh�F�{�ɯg���D�n�]�A�o�N�B�y�¡B�Y�h�B�٦׵h�B�h�¡B�y����B���V�h���F�y�P���F�z�o�y��ֳt�B�����d��s�x���S�⤧�~�A�ٷ|�����Y���ֵo�g�Φ��`�A�ثe�ڰ�N�u�y�P�ֵo���g�v�C���ĥ|���ǬV�f�C

�ܬy�P�ī~�D�n����3�j���G
�@�BM2 protein���(Amantadine�MRimantadine)
��A���y�P���ġA�]���ĩʯf�r�褣�_�W�[�A���F�Y�Ǫ��p�~�A����e�f�ި����ij�ϥΦ��Īv��A���y�P�C
�G�B���g�i��酶���(Zanamivir, Oseltamivir, Peramivir)
�Ω�w���Ϊv��A���PB���y�P�A�i����neuraminidase�����ʡA�y���f�r�E���L�k���X�C�ثe�̱`�ϥά�Oseltamivir (Tamiflu®�J�y�P)�BZanamivir (Relenza Diskhaler®��֨F梹F��) �T�BCap�̿૬�f�r����酶���(Baloxavir marboxil)

2018�~10�����s�֭㪺�ܬy�P�ī~�A�g���}�l48�p�ɤ��A�Τ@�����Īv���y�P�A�s��Xofluza®�����Цp�U�G
�iXofluza�Ī�����P�A���g�j
Baloxavir marboxil�OCap�̿૬�f�r����酶����]cap-dependent endonucleaseinhibitor�^�C�ѩ�O�e�X�ġA�A�Ϋ�ݦb�餺���Ѭ����Ĭ��ʦ���baloxavir�A�B�����f�r�E�X酶�ĩʮֻĤ���酶�]polymerase acidic endonuclease�^�����ʡA�F�����f�rRNA����@�ΡA����f�r���ƻs�C
���ĥΩ�v��12���H�W����ʬy�P�]acute uncomplicated influenza�^�g�����W�L48�p�ɪ��w�̡CA���PB���y�P�w�̬ҥi�H�ϥΡC
�iXofluza�Ϊk�ζq�P�ϥΤ�k�j
�u�ݪA�γ�@�����q�]single dose�^�A�P�����Τ��P�����֪A�ҥi�C�@��뤩�����q�O�̾ڱw���魫�M�w�C
�魫40����ܡ�80����A��@���q40mg�F�魫80����H�W�A��@���q80mg
�iXofluza�椬�@�Ρj
Baloxavir marboxil ���קK�P�t�h�������l�w�m���B��ľ��Τf�A���l�ɥR���]�Ҧp�t�B�K�B��Bִ�B�N�^�֥ΡA�|���Xofluza���夤�@�סA���C���Ī��ĪG�C
�iXofluza�Ƨ@�Ρj
�`�����Ƨ@�Φ����m(3%)�B���ު�(2%)�B��|��(1%)�B����(1%)�B�Y�h(1%)�C

�ĤQ���G�Ī� - ����A�i (Rimantadine)

[ back ]

²��
(���s��: �K�O����\��)

����A�i(Rimantadine)�OM 2���l�q�D���(M2 ion channel inhibitor)�A��z�Z�f�r����h�~�M�ߪ��@��(uncoating process)�A�q�ӧ���y�P�үf�r(influenza A)���ۧڽƻs��O�CM 2��������b�f�r������M 2�J�����l�q�D(Hay 1985, Sugrue 1991)�C�򥻤W�A�y�P�f�r�|�z�L���餶�ɪ����]�@��(receptor-mediated endocytosis)�Ӷi�J�H�D�ӭM(host cell)�A�M�᤺�]�w�n(endocytotic vesicles)�i��ĤƧ@�ΡA�NM 1�J�եѮֿ}�ֳJ�սƦX��(ribonucleoprotein complexes)�����X�ӡC����ֿ}�ֳJ�ժ�(ribonucleoprotein particles)�~�i�z�L�֤նi�J�ӭM�֡C�����ĤƧ@�άO�n�B���l�A�B���l�N�O�z�LM 2���l�q�D�ǰe�C����A�i(Rimantadine)��������릹���l�q�D(Bui 1996)�C

����A�i(Rimantadine)���Ҧ��y�P�үf�r�ȸs(influenza A subtypes)���@�w�ĥΡA�p��P�f��H1N1�BH2N2��H3N2�f�r�C�����y�P�A�f�r�N������ġA�]��M 2�J�զb�y�P�үf�r�O�W�S���C����A�i(Rimantadine)������ɭP�H���V�f��H5N1�V�y�P�f�r�]�_����@��(Li 2004)�C

�ܩ�ҫ��y�P���w���Ϊv���譱�A����A�i(Rimantadine)�Ϊ����iAmantadine��̮į�t���h�A������A�i(Rimantadine)���־��|�ް_���}����(Stephenson 2001, Jefferson 2004)�C

����A�i(Rimantadine)�򥻤W�S���v�T�����y�P�r�誺���M�@�ΡA������G��IgA�ƶq��������(Clover 1991)�C

����o����s��ܡA��Q�~�����amantadine�Χܪ���A�i(Rimantadine)�ʪ�H3N2�f�r���P�V�Ӯפ��_�W�ɡC���i���X�A�b1994-2005�~���A�����F���y7,000�ӥҫ��y�P�f�r�˥��A�ӹ�amantadine�Ϊ���A�i(Rimantadine)�X�{���Ĥ�������0.4%�ɦ�12.3%(Bright 2005)�C�A�̡A�ѫn���B�x�W�B����Τ���Ҧ����^�ӯf�r�˥��A���������Ĥ��������O��15%�B23%�B70%��74%�C�̪�A����q�f�H���W���H3N2�y�P�f�r����A�o�{�f�r��M 2�J�ժ��i���31��m�X�{�ܲ��A�ӳo��m�N�O���͹�amantadine�Ϊ���A�i(Rimantadine)���ĩʡC���H�W��]�A����e�f����߫�ij�b2005-06�~�׾l�U���y�P�u�`���n�ĥ�amantadine�Ϊ���A�i(Rimantadine)�@�v���ιw���y�P�γ~(CDC 2006)�C

�b�ܦh��a�A����A�i(Rimantadine)�w���A�q�ΡC

�ƾǵ��c

����A�i(Rimantadine)�Q�ĬOalpha-methyltricyclo-[3.3.1.1/3.7]decane-1-methanamine hydrochloride�A����l���q��215.77�ε��c�p�U�G

Rimantadine機轉

�Ī��N�°ʤO��

�b���d���H���A���f�A�Ī���A�j��6�p�ɦ�G���@�׬��̰��C�b���H(Hayden 1985)�Ψൣ(Anderson 1987)�����Ī��b�I������30�p�ɡC����j�����Ī������b�xŦ�i��N�¡A�u���֩�25%���q�����N�§��ܦӸg�p�K�ƥX�C�b�ѤH���A�Ī��b�餺�����һݮɶ������A�Ψ�AUC�ȤΦ�G�̰��@�פ]���󰷱d���H20-30%�C

�b�@�릳�C�ʨx�f���w�̡A�����A�i(Rimantadine)�Ī��ʤO�ǬO���|���ܪ�(Wills 1987)�C�ۤϡA���Y���xŦ���ॢ�դ��w�̡A��AUC�ȤΥb�I�����|�W�[�C

�p��Ŧ���ॢ�աA�i�ɭP��G������A�i(Rimantadine)�N�ª��@�פɰ��C��G�z�R�]���ణ�h����A�i(Rimantadine)�A�G����󥽴��ǯf�w�̡A����A�i(Rimantadine)���q������֡C�i���G�z�R�����A�]���θɥR���q(Capparelli 1988)�C

�r��

�G�z�D�x���O�]�A�Ϊ���A�i(Rimantadine)��̦h�X�{�����}�����C�b�{�ɸ��礤�A�֩�3%�X�{��L���}�����A�p�Y�w�B�æR�B�����B�f���Τ��ϯ��g�x��(���v�B�Y���B���g��i)�C�ۤϡA�ѦҦb���i�|�����A�Ϊ���A�i(Rimantadine)�@�w�����H�h���p���A������w���ʤήį�ʪ���s�A�o�{�򥻤W�A�Ϊ���A�i(Rimantadine)�S������a�Ӥ���G�z�D�Τ��ϯ��g�x�������}����(Monto 1995)�C

�٦��@�Ǹ��֨������}�x��(0.3 to 1%)�A�p�{�m�B���Ƥ��}�B���ධ���믫�B�ʧ@���ण��աB�ݺΡB�gļ�B���{�B�X�l�B�ջ�ή�ݡC

���@�Ǧ��j�˥v�S����S���A�Τ�j�Ĥ��H�h�A����A�i(Rimantadine)���i�໤�o��j�˱��p�C���J���������p�A���ߨ谱��A�Ϊ���A�i(Rimantadine)�C

�@��ӻ��A�H�W�ҭz���}�����h�b���A����A�i(Rimantadine)������C ����Ŧ�ΨxŦ���դ��w�̹����A�i(Rimantadine)���w���ʤ��Ī��ʤO�ʡA�u����榸���ƫ��������ơA�]����Ŧ�ΨxŦ���շ|�ɭP����A�i(Rimantadine)�Ψ�N�ª��n�E���G��������f�H�I�����S�O�p�ߡC

�{�b�S���@�����n���������P�A�Ϊ���A�i(Rimantadine)���w���ʬ�s�A�ҥH�ڭ̥��ij����A�i(Rimantadine)���A�X�󥥰��A�ΡC�P�ˡA����A�i(Rimantadine)�]���A�X���Ťk�h�A�ΡA�]�b�ѹ����礤�A�o�{�¥��Ū��p���餺������A�i(Rimantadine)�����C

�b�P�@���q�������礤�A����A�i(Rimantadine)��amantadine�����@�ĩ�(Jefferson 2004)�C���������رw�̤����A�o�{�]�X�{���ϯ��g���}�����Ӱ��Ϊ���A�i(Rimantadine)��amantadine���A��?��6%��13%(Dolin 1982)�C

�į��

����A�i(Rimantadine)������v�h�H����H5N1�V�y�P�f�r�_���쬡�ʧ@��(Li 2004)�C����A�i(Rimantadine)�����ĩ�w���Ϊv���DzΤH���`�X�{���ҫ��y�P�P�V(H1N1, H2N2 and H3N2)�C����A�i(Rimantadine)���į�ʬO�i��o�W�����i(amantadine)���C�ۤϡA�bCochrane���׽Ƭd3�ئw������Ӵ��դU�A�o�{����A�i(Rimantadine)�u���y�P�Ӯפάy�P�æ��Ӯװ_�F�w�M�@��(Jefferson 2006)�C�b�v���L�{���A����A�i(Rimantadine)���Y�u�o�N�ɶ��νw�M�]�ҫ��P�_�Ӭy��������p�C�����y�P���X�F�@�Ǥ��}���p�A����A�i(Rimantadine)���į�|�j�j���C�C�����`���A �����yM 2���l�q�D����A�]�A����A�i(Rimantadine)�Ϊ����i(amantadine)�A�v���u�`�ʤΥ��y�y��ʷP�_(Jefferson 2006)(��²����CDC��ij)�C

�v��

�b�������ըǷP�V�D������H3N2�ҫ��y�P���w�̡A�Ϊ���A�i(Rimantadine)�v��(�C��200�@�J�A����5��)�۹�󱵨��w�����̥i�����֤F��G���c�����f�r�@�סB�̰��ūסB�o�N�ɶ�(����ơA�ֹL37�p��)�Υ����x��(Hayden 1986)�C�ϥΪ���A�i(Rimantadine)������i�|�����`�g�̭]�ѤH���G�ᬰ�w��(Monto 1995)�C�N�H�W�H�h�ӻ��A���q�̦n���C��C��100�@�J�C�t�~�A��@����P�V���H�i����աA����A�i(Rimantadine)���|�v�T��Ķ}�q�B�H�G�M�j�B��ļx���Φճ��ֵo�g(Doyle 1998)�C

�w��

����A�i(Rimantadine)���w���į�v�ܤƫܤj�C�Ƭd�{�ɬ�s�A����A�i(Rimantadine)���w���IJv�F64%�A�Ω���o�N�ɶ��Y�u�F1.27��(Demicheli 2000)�C����A�i(Rimantadine)���ൣ�]�i�঳��(Clover 1986, Crawford 1988)�C

���ĩ�

��M��]�X�{���ܫ�ӭPM2�J�ժ����ħ��ܡA�ܮe���y�������A�i(Rimantadine)�����ק��ĩʡC�o�ج��ܤF���f�r�O�M���ͫ��@�˦��r�ʤήe���Ǽ����Iŧ�ʯf�r�A�i�ް_�嫬�y�P�P�V�C�j���T�����@���w�̥X�{���ĩʡC�K�̯�O�V�t���w�̡A�X�{���ĩʶV�j(Englund 1998)�C���Ǧ��o�ͪ��Ҥl(H3N2)�A�Ϊ���A�i(Rimantadine)���ൣ�Φ��H�w�̡A��Ѥ���K����o����ĩʥҫ��y�P�f�r(Hayden 1991)�C

�f�r�Ǽ���O�O�ϥΪ���A�i(Rimantadine)���@�ӭ��n�M�w�C������s�w���y�P�P�V���Ѫ���]���G�O�]�����ĩʯf�r�]�l�Ǽ��C�]����s�`���A����A�i(Rimantadine)����㦳�O�@�a�~�����V�ҫ��y�P���|(Hayden 1989)�C

�b2003-2004�~���A���b�F�n�ȸv�h�H����H5N1�V�y�P�f�r�A�O�����A�i(Rimantadine)�㦳���Ĥ���(���Ĵݯd���bM2�J��31��m)(Li 2004)�C

��Q�~�A��amantadine�Ϊ���A�i(Rimantadine)���Ĥ����A��0.4%�W��12.3%(Bright 2005)�C

�Ī��ۤ��@��

�{�ɤW�A�S���o�{����A�i(Rimantadine)���L�Ī��������ۤ��@�ΡCCimetidine�i�঳���|��C����A�i(Rimantadine)���M�j�v�F18%(Holazo 1989)�CAcetaminophen�N�i���C����A�i(Rimantadine)�b��G�@�פ�AUC�Ȭ�11%�CAspirin�h�i���C����A�i(Rimantadine)�b��G�@�פ�AUC�Ȭ�10%�C

��ij�ϥ�

�b�ڷ���a�A�t����A�i(Rimantadine)���ĥβ��~�w����a�{�i(������ơA�аѦҳB����)�C

�b����A����A�i(Rimantadine)�Q�C�@���ൣ�Φ��H�w���y�P���ΡC���v���譱�A�u�C�@�����H�ϥΡC����A�i(Rimantadine) (Flumadine?)�s��100�@�J���n�Ĥ��Τf�A�IJG�����C

���H

�b����A��ij�w���Ϊv�����q��100�@�J�C��G���C

�Y�DZw�̪��ϥξ��q����֦ܨC��100�@�J�G

  • �Y���xŦ���ॢ��
  • �ǰI�� (CrCl≤10�@��/����)
  • �b�w�Ѱ|���w��(Patriarca 1984, Monto 1995)

�p�w�̦�����ǥ\�ॢ�աA���K���d�N�A���H���p���ܾ��q�C

�v���譱�A���X�{�ҫ��y�P�x����A48�p�ɤ��A�Ϊ���A�i(Rimantadine)�C���{�̦n���o�f��7�ѡC

�ൣ

�b����A����A�i(Rimantadine)�u�A�Ω�w���γ~�C10���H�U�ൣ����5�@�J/������q�A�Τ���h��150�@�J�����q�C10���ΥH�W�ൣ�i�����H���q�A�ΡC

ĵ�i

������w�g�w�̡A�A�Ϊ���A�i(Rimantadine)�n�󬰤p�ߪ`�N�C

�`��

�ӼЦW�١GFlumadine®

�Ī������GM2 ���

�Ϊk�G�w��(���H�Ψൣ)�Ϊv��(���H)�ҫ��y�P�P�V�C����A�i(Rimantadine)�v���譱�A���X�{�x����48�p�ɤ��A�ΡC

�зǪv�����q�G100�@�J�C��2��

����Y���xŦ���ॢ�աB�ǰI�� (CrCl≤10�@��/����)�Φb�w�Ѱ|���w�̡A �ϥξ��q����֦ܨC��100�@�J�C

�зǹw�����q�G100�@�J�C��2��
����Y���xŦ���ॢ�աB�ǰI�� (CrCl?10�@��/����)�Φb�w�Ѱ|���w�̡A�ϥξ��q���֦ܨC��100�@�J�C10?�H�U�ൣ����5�@�J/������q�A�Τ���h��150�@�J�����q�C10?�ΥH�W�ൣ�i�����H���q�A�ΡC

�Ī��ʤO�ǡG���f�A�Ī����6�p�ɡA�Ī��@�צb��G���F�̰��C�Ī��b�I������30�p�ɡC�Ī��b�ѤH�b�餺�����ɶ������C�j�����Ī������b�xŦ�i��N�¡A�u���֩�25%���q���ܦa�g�p�K�ƥX�C�Ӥ@���Y����Ŧ�ΨxŦ���ձw�̡A���Ī��b��G�����@�׷|�W�ɡC

�ۤ��@�ΡG�L����ۤ��@��

�Ƨ@�ΡG�G�z�D�x��

�Ѧ�

  1. Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother 1987; 31: 1140-2. Abstract: http://amedeo.com/lit.php?id=3662473 - Full text at http://www.pubmedcentral.gov/articlerender.fcgi?pubmedid=3662473
  2. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62: 1508-12. Abstract: http://amedeo.com/lit.php?id=3282079
  3. Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430-5. Abstract: http://amedeo.com/lit.php?id=2915166
  4. Brady MT, Sears SD, Pacini DL, et al. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob Agents Chemother 1990; 34: 1633-6. Abstract: http://amedeo.com/lit.php?id=2285274
  5. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81. Epub 2005 Sep 22. Abstract: http://amedeo.com/lit.php?id=16198766
  6. Bui M, Whittaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996; 70: 8391-401. Abstract: http://amedeo.com/lit.php?id=8970960 - Full text at http://jvi.asm.org/cgi/reprint/70/12/8391?pmid=8970960
  7. Capparelli EV, Stevens RC, Chow MS, Izard M, Wills RJ. Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure. Clin Pharmacol Ther 1988; 43: 536-41. Abstract: http://amedeo.com/lit.php?id=3365917
  8. CDC 2006. CDC Recommends against the Use of Amantadine and Rimantadine for the Treatment or Prophylaxis of Influenza in the United States during the 2005-06 Influenza Season. Available from http://www.cdc.gov/flu/han011406.htm - Accessed 13 February 2006.
  9. Clover RD, Crawford SA, Abell TD, Ramsey CN Jr, Glezen WP, Couch RB. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child 1986; 140: 706-9. Abstract: http://amedeo.com/lit.php?id=3521258
  10. Clover RD, Waner JL, Becker L, Davis A. Effect of rimantadine on the immune response to influenza A infections. J Med Virol 1991; 34: 68-73. Abstract: http://amedeo.com/lit.php?id=1885945
  11. Crawford SA, Clover RD, Abell TD, Ramsey CN Jr, Glezen P, Couch RB. Rimantadine prophylaxis in children: a follow-up study. Pediatr Infect Dis J 1988; 7: 379-83. Abstract: http://amedeo.com/lit.php?id=3292997
  12. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030. Abstract: http://amedeo.com/lit.php?id=10590322
  13. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580-4. Abstract: http://amedeo.com/lit.php?id=7050702
  14. Doyle WJ, Skoner DP, Alper CM, et al. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 1998; 177: 1260-5. Abstract: http://amedeo.com/lit.php?id=9593010 - Full text at http://www.journals.uchicago.edu/cgi-bin/resolve?JIDv177p1260PDF
  15. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418-24. Abstract: http://amedeo.com/lit.php?id=9636873 - Full text at http://www.journals.uchicago.edu/cgi-bin/resolve?CIDv26p1418PDF
  16. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80: 275-82. Abstract: http://amedeo.com/lit.php?id=3302925
  17. Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother 1985; 28: 216-21. Abstract: http://amedeo.com/lit.php?id=3834831 - Fulltext at http://www.pubmedcentral.gov/articlerender.fcgi?pubmedid=3834831
  18. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986; 29: 339-41. Abstract: http://amedeo.com/lit.php?id=3521480
  19. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696-702. Abstract: http://amedeo.com/lit.php?id=2687687
  20. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35: 1741-7. Abstract: http://amedeo.com/lit.php?id=1952841
  21. Holazo AA, Choma N, Brown SY, Lee LF, Wills RJ. Effect of cimetidine on the disposition of rimantadine in healthy subjects. Antimicrob Agents Chemother 1989; 33: 820-3. Abstract: http://amedeo.com/lit.php?id=2764530 - Full text at http://www.pubmedcentral.gov/articlerender.fcgi?pubmedid=2764530
  22. Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev 2004; CD001169. Abstract: http://amedeo.com/lit.php?id=15266442
  23. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367: 303-13. Abstract: http://amedeo.com/lit.php?id=16443037
  24. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430: 209-13. Abstract: http://amedeo.com/lit.php?id=15241415
  25. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39: 2224-8. Abstract: http://amedeo.com/lit.php?id=8619572 - Full text at http://aac.asm.org/cgi/reprint/39/10/2224
  26. Patriarca PA, Kater NA, Kendal AP, Bregman DJ, Smith JD, Sikes RK. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes. Antimicrob Agents Chemother 1984; 26: 101-3. Abstract: http://amedeo.com/lit.php?id=6476812
  27. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001; 17: 1282-93. Abstract: http://amedeo.com/lit.php?id=11491177 - Full text at http://erj.ersjournals.com/cgi/content/full/17/6/1282
  28. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991; 180: 617-24. Abstract: http://amedeo.com/lit.php?id=1989386
  29. Wills RJ, Belshe R, Tomlinsin D, et al. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease. Clin Pharmacol Ther 1987; 42: 449-54. Abstract: http://amedeo.com/lit.php?id=3665342
  30. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995; 29: 299-310. Abstract: http://amedeo.com/lit.php?id=7606077